Carna Biosciences, Inc.
Carna Biosciences, Inc. scores highest on Nitro (53) and lowest on Price (0). Its PosiPenta is 27.79 out of 100, weaker than most similar companies.
On the Penta Grid this week, Carna Biosciences, Inc. is Grid #52 of 53 in the Healthcare sector in Japan, and Grid #1,024 of 1,059 in Japan.
Compared with similar companies in the Healthcare sector in Japan.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Carna Biosciences, Inc. | 27.79 | 0 | 45 | 53 | 4 | 37 |
| Cosmo Bio Company,Limited | 58.42 | 62 | 55 | 60 | 57 | 58 |
| Koken Ltd. | 60.00 | 90 | 80 | 33 | 39 | 58 |
| Yamashita Health Care Holdings,Inc. | 65.52 | 64 | 87 | 70 | 50 | 57 |
| CellSource Co., Ltd. | 46.66 | 42 | 60 | 20 | 77 | 35 |
| Create Medic Co., Ltd. | 61.79 | 67 | 53 | 79 | 51 | 59 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -3.13 |
| P/B ratio | -18.10 |
EEarnings
| Trailing EPS | ₹-67.47 |
| Forward EPS | ₹68.22 |
NNitro
| Price | 211.27 |
| 52-week high | 309.95 |
| 52-week low | 121.07 |
| Fall from 52-week high | 31.8% |
TTorque
| Return on equity (ROE) | -438.70% |
| Debt-to-equity | 2.31 |
AAnchor
| Beta (price swings) | 0.28 |
| Market cap | ₹446 Cr |
| Insider holding | 26.48% |
| Dividend yield | 0.00% |
Figures as used for the week of 24 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Carna Biosciences, Inc.'s PosiPenta score?
Carna Biosciences, Inc.'s PosiPenta is 27.79 out of 100 for the week of 24 Oct 2026, based on 5 of 5 pillars.
Where does Carna Biosciences, Inc. stand on the Penta Grid?
On the Penta Grid this week, Carna Biosciences, Inc. is Grid #52 of 53 in the Healthcare sector in Japan, and Grid #1,024 of 1,059 in Japan.
Which PosiPenta pillar is strongest for Carna Biosciences, Inc.?
Nitro (momentum), with a score of 53 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Carna Biosciences, Inc.?
Price (valuation), with a score of 0 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.